CTMX
CytomX Therapeutics Inc
NASDAQ: CTMX · HEALTHCARE · BIOTECHNOLOGY
$4.05
-1.70% today
Updated 2026-04-29
Market cap
$951.18M
P/E ratio
—
P/S ratio
12.48x
EPS (TTM)
$-0.15
Dividend yield
—
52W range
$1 – $8
Volume
7.6M
CytomX Therapeutics Inc (CTMX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-22.80%
Operating margin
-3,791.00%
ROE
-35.20%
ROA
-8.99%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2013 | $888000.00 | $-15.14M | 100.00% | -1,684.23% | -1,705.29% |
| 2014 | $5.08M | $-30.31M | 100.00% | -586.27% | -597.01% |
| 2015 | $7.71M | $-35.37M | 100.00% | -430.54% | -458.69% |
| 2016 | $15.04M | $-58.90M | 100.00% | -396.10% | -391.54% |
| 2017 | $71.62M | $-43.10M | 100.00% | -64.59% | -60.17% |
| 2018 | $59.50M | $-84.60M | 100.00% | -130.88% | -142.19% |
| 2019 | $57.49M | $-102.24M | 100.00% | -192.90% | -177.84% |
| 2020 | $68.43M | $-64.82M | 100.00% | -117.70% | -94.73% |
| 2021 | $69.57M | $-80.65M | 100.00% | -120.42% | -115.92% |
| 2022 | $53.16M | $-97.30M | 100.00% | -190.61% | -183.02% |
| 2023 | $101.21M | $-569000.00 | 100.00% | -6.41% | -0.56% |
| 2024 | $138.10M | $31.87M | 100.00% | 18.10% | 23.08% |
| 2025 | $76.20M | $-17.37M | 100.00% | -25.67% | -22.79% |